


MOCCA –APGOT OV2



A Multicentre Phase II randomised trial of MEDI4736 (DURVALUMAB) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinomas (MOCCA) (NCT03405454)



Singapore PI: David Tan NUH GCGS (CI)
Australia PI: Michael Friedlander ANZGOG
Korean PI: Kidong Kim KGOG
Trial Statistician: Prof Tai Bee Choo (NUS)

MOCCA updates




Recurrent Clear Cell Cancer Ovarian Cancer (>70% clear cell)

Inclusion

- WT1 negative
- Relapsed after at least 1 line of platinum-based chemotherapy
- Measurable disease by RECIST 1.1
- ECOG 0-2

Exclusion

- Previous exposure to immune-checkpoint inhibitor



Primary Endpoint: Median PFS improvement from 10 weeks to 20 weeks

MOCCA updates

1. Recruitment completed in June 2020.
2. All patients have gone off trial in Singapore, but we still have 2 subjects in Korea and 3 subjects in Australia remaining on study.
3. Database currently being cleaned.
4. All sites PIs and coordinators are strongly encouraged to address the data queries issued so far and close them so that we can be on target to ready the data for analysis.